A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain

Journal of Pain and Symptom Management

Volumn 47, Issue 6, 2014, Pages 1001-1007

  Taylor, Donald ^a   Radbruch, Lukas ^b   Revnic, Julia ^c   Torres, Luis M ^d   Ellershaw, John E ^e   Perelman, Michael ^f  

^a Georgia Center for Cancer   (United States)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Jean Jaurès Hospital   (France)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^e Marie Curie Palliative Care Institute   (United Kingdom)

^f Albert Einstein Centre   (United Kingdom)

Author keywords

Breakthrough; cancer; fentanyl; FPNS; long term; pain; palliative care

Indexed keywords

FENTANYL; MORPHINE; PECTIN; DRUG COMBINATION; NARCOTIC ANALGESIC AGENT; NOSE SPRAY;

ADULT; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BREAKTHROUGH PAIN; BREAST CANCER; CANCER PAIN; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FEMALE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; PAIN; PERIPHERAL EDEMA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SLEEP DISORDERED BREATHING; THORAX PAIN; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; DRUG COMBINATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; TIME; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; DRUG COMBINATIONS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MORPHINE; NASAL SPRAYS; NEOPLASMS; PALLIATIVE CARE; PECTINS; TIME FACTORS; YOUNG ADULT;

EID: 84902506052     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2013.07.012     Document Type: Article

References (18)

1. R. McCorkle, E. Ercolano, and M. Lazenby et al. Self-management: enabling and empowering patients living with cancer as a chronic illness CA Cancer J Clin 61 2011 50 62
2. F.D. Ferris, E. Bruera, and N. Cherny et al. Palliative cancer care a decade later: accomplishments, the need, next steps - from the American Society of Clinical Oncology J Clin Oncol 27 2009 3052 3058
3. T.D. Starr, L.J. Rogak, and S.D. Passik Substance abuse in cancer pain Curr Pain Headache Rep 14 2010 268 275
4. T.J. Smith, S. Temin, and E.R. Alesi et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care J Clin Oncol 30 2012 880 887
5. R.K. Portenoy, and P. Lesage Management of cancer pain Lancet 353 1999 1695 1700
6. A.N. Davies, A. Dickman, C. Reid, A. Stevens, and G. Zeppetella The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland Eur J Pain 13 2009 331 338
7. R.K. Portenoy, W. Raffaeli, and L.M. Torres et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients J Opioid Manag 6 2010 319 328
8. J. Schey Fentanyl nasal spray: a new option for breakthrough cancer pain J Adv Pract Oncol 2 2011 402 405
9. Lazanda [package insert] 2012 Archimedes Pharma US Inc. Bedminster, NJ
10. PecFent summary of product characteristics 2012 Archimedes Development Ltd. Nottingham, UK
11. R.K. Portenoy, A.W. Burton, N. Gabrail, D. Taylor Fentanyl Pectin Nasal Spray 043 Study Group A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain Pain 151 2010 617 624
12. D. Taylor, V. Galan, and S.M. Weinstein et al. Fentanyl pectin nasal spray in breakthrough cancer pain J Support Oncol 8 2010 184 190
13. M. Fallon, C. Reale, A. Davies Fentanyl Nasal Spray Study 044 Investigators Group Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study J Support Oncol 9 2011 224 231
14. A. Davies, T. Sitte, and F. Elsner et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain J Pain Symptom Manage 41 2011 358 366
15. L. Radbruch, L.M. Torres, and J.E. Ellershaw et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain Support Care Cancer 20 2012 565 573
16. H. Smith A comprehensive review of rapid-onset opioids for breakthrough pain CNS Drugs 26 2012 509 535
17. J.V. Pergolizzi Jr., C. Gharibo, and S. Passik et al. Dynamic risk factors in the misuse of opioid analgesics J Psychosom Res 72 2012 443 451
18. Substance Abuse and Mental Health Services Administration Results from the 2011 National Survey on Drug Use and Health: Summary of national findings NSDUH Series H-44, HHS Publication No. (SMA) 12-4713, 1-174. 2012 2012 Substance Abuse and Mental Health Services Administration Rockville, MD